Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Agios announces new data on mitapivat will be featured in oral and poster presentations at EHA 2026 in Stockholm, Sweden, June 11-14, 2026
-
Agios announces first quarter 2026 financial results and provides business update.
-
PYRUKYND (mitapivat) approved for adults with thalassemia in the United Arab Emirates
-
Agios (Nasdaq: AGIO) announces financial results and updates for the fourth quarter and year ended December 31, 2025.
-
Agios today announced its 2026 strategic priorities and key milestones anticipated during the year.
-
Agios today announced that the U.S. FDA has approved AQVESME™ (mitapivat), an oral pyruvate kinase (PK) activator, for thalassemia
-
Agios today announced that the U.S. Food and Drug Administration (FDA) has not yet issued a regulatory decision on the sNDA for mitapivat in thalassemia
-
Agios today announced financial results and updates for the third quarter ended September 30, 2025.
-
Agios today announced that the CHMP has adopted a positive opinion for the new indication for PYRUKYND in adults for anemia associated with thalassemia
-
New York, USA, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Thalassemia Treatment Market to Witness Significant Growth by 2034 Driven by Novel Drug Development | DelveInsight The thalassemia market is...